君實生物(688180.SH)將於7月15日在科創板上市
格隆匯 7 月 13日丨君實生物(688180.SH)發佈首次公開發行股票科創板上市公告書，發行股份數量為8713萬股，佔此次發行後總股本的10%，全部為公司公開發行新股；發行價為55.5元/股；將於2020年7月15日在上海證券交易所上市。
發行人預計2020年1-6月可實現營業收入45572.31萬元至56072.31萬元，同比增長47.34%至81.28%，預計2020年1-6月歸屬於母公司股東的淨利潤-68069.12萬元至-56283.46萬元，同比增長-133.97%至-93.46%，預計2020年1-6月扣除非經常性損益後歸屬於母公司所有者的淨利潤-66483.83萬元至-54698.18萬元，同比增長-115.76%至-77.51%。2020年1-6月發行人收入增幅較大，主要原因為：公司產品“特瑞普利單抗”於2018年12月正式獲得NMPA有條件批准並於2019年2月末起開展銷售，憑藉市場先發優勢、良好的產品臨牀療效、產品價格優勢、經驗豐富的銷售團隊、高效的銷售組織體系建設和符合產品特性的市場推廣方案，公司2020年上半年收入較2019年上半年增幅較大。
根據發行人2020年1-6月業績預計，發行人預計2020年1-6月歸屬於母公司股東的淨利潤-68069.12萬元至-56283.46萬元，同比增長-133.97%至-93.46%，預計2020年1-6月扣除非經常性損益後歸屬於母公司所有者的淨利潤-66483.83萬元至-54698.18萬元，同比增長-115.76%至-77.51%，預計虧損進一步擴大。主要原因為：公司自設立以來專注於藥品研發，隨着JS001的適應症擴展以及部分臨牀項目進度推進、海外臨牀的開展，連續數年發生較大的研發費用支出；公司首個產品於2019年2月起剛開始實現銷售，銷售收入尚不能覆蓋研發費用等支出。
公司儲備了多項處於早期臨牀前研究階段的在研項目，公司未來仍需持續較大規模的研發投入用於在研項目完成臨牀前研究、臨牀試驗及新藥上市前準備等產品管線研發業務，且公司新藥上市申請、新藥市場推廣等方面亦將帶來高額費用，均可能導致公司虧損進一步擴大，從而對公司日常經營、財務狀況等方面造成不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
